NBEAL2

Across TCGA pan-cancer cohorts, NBEAL2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated NBEAL2 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher NBEAL2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NBEAL2 expression acts as an unfavorable survival marker, although some lineages such as READ and SKCM show a favorable association.

ACC, STAD, and UCEC are the cancer types where NBEAL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.120	0.772	<.001	30	view →
STAD	OS	Median	IV	0.074	0.496	.002	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
LIHC	OS	Median	II,III,IV	0.308	0.710	<.001	11	view →
LUAD	OS	Median	II,III,IV	0.313	0.714	<.001	10	view →
MESO	DFS	Median	All	0.099	0.392	.030	9	view →
ESCA	DFS	Median	All	0.261	0.539	.038	6	view →
READ	DFS	Median	All	1.000	0.486	.035	5	view →
SARC	OS	Median	All	0.238	0.826	.001	3	view →
SKCM	OS	Median	All	0.858	0.351	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

NBEAL2–ACC (DFS)

Open the ACC breakdown →